Caraco Pharmaceuticals to market generic Nimotop

Apr 30 2007

Caraco Pharmaceutical Laboratories has announced that it will market Nimodipine Capsules, 30mg (Nimotop) on behalf of Sun Pharmaceutical Industries, Inc. (Sun), a wholly owned subsidiary of Sun Pharmaceutical Industries, Ltd.

Sun recently received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nimodipine.

Nimodipine is a cardiac drug and belongs to the class of calcium channel blockers. This new product is bioequivalent to Nimotop(R), a registered trademark of Bayer Pharmaceuticals. Nimotop(R) had U.S. sales of approximately $26.8 million for the 12-month period ended Dec. 31, 2006, according to IMS Data. Caraco is the first company to market the generic version of Nimotop(R) and has one strength available, 30mg soft gelatin capsules.

Daniel H. Movens, Caraco's Chief Executive Officer, said, "We are pleased to be the first company to market generic Nimotop(R). It is also the first ANDA approved by the FDA for Sun Pharmaceutical Industries, Inc. out of Cranbury, New Jersey. We continue to focus on working towards expanding our product offering as quickly and effectively as possible. We plan to launch this product as the first entrant in the generic pharmaceutical market immediately. This will bring our total product selection to 30 different products represented by 66 various strengths."